Vetted by NeuralPress's Multi-Agent Verifier for strict factual validity and event relevance. Our compliance engine cross-checks and filters search results to ensure zero false correlations or misleading content.
Primary Sources
Colorectal Cancer Screening: Which test would I prefer? - Health
Everyone ages 45 to 75 years needs to get screened for colorectal cancer. Screening saves lives because it can help catch cancer early, when it’s easier to treat. There are 3 main types of colorectal cancer screening tests: colonoscopy, flexible sigmoidoscopy, and stool tests. Each test has pros and cons. To find out which test you might prefer, answer the following questions. Questions like these can help patients make health care decisions that fit their preferences. Then share the results with your doctor. Together, you and your doctor can choose the best test for you.
NHS trial puts AI for breast cancer screening under scrutiny
News Nearly 700,000 women will be recruited into an NHS trial of artificial intelligence (AI) tools for breast cancer screening in an attempt to spot the disease earlier and save lives. The EDITH (Early Detection using Information Technology in Health) study was announced by the Department of Health and Social Care (DHSC) this morning – World Cancer Day – and supported by £11 million in government support provided by the National Institute for Health and Care Research (NIHR). It will compare various AIs to see if they can enhance breast cancer screening and will form the basis of a "call for evidence" on ways to reduce lives lost to cancer, improve the efficiency of the NHS, and assist in the digital transformation of the health service. From April, women invited for a routine breast cancer screening will be invited to take part in the trial at 30 testing sites across the country. The AIs will be tested to see how well they can assist radiologists in interpreting mammograms and identifying changes in breast tissue that could signal cancer. Currently, two radiologists are required to review the images from each screening, but the hope is that this could be reduced to one with AI. That could free up radiologists' time and – potentially, at least – provide results more quickly and reduce waiting lists. More than two million mammograms are carried out each year under the NHS screening programme, which is offered every three years to women from the age of 50 upwards. The trial has the support of the Royal College of Radiologists (RCR), which has called on the UK to embrace AI to help solve chronic understaffing in the sector, with around 30% fewer radiologists in the NHS than are currently needed. The RCR recently reported data showing that hundreds of thousands of scans took longer than a month to be reviewed, which is a breach of NHS targets. While AI could be a solution to that problem, it will take time for the technologies to be fully tested and validated to make sure they don't put patients at risk and waste NHS time and resources, according to RCR president Dr Katharine Halliday, who delivered a keynote speech at a conference on the role of AI in the NHS yesterday. In the meantime, there is an "urgent" need to tackle the staffing crisis and "build radiology capacity," she said, adding that the rollout of AI must be done with "expert oversight" to make sure it is safe and effective. In the wake of the Darzi report, which found cancer survival in the UK i...
The New Frontier of Cancer Treatment: Bispecific ADCs | BioPharm ...
Bispecific antibody-drug conjugates are reshaping oncology drug development, with izalontamab brengitecan (iza-bren) emerging as a potential first-in-class therapy targeting EGFR and HER3 pathways. This dual-targeting ADC delivers a topoisomerase 1 inhibitor directly into tumor cells, addressing resistance mechanisms that limit conventional treatments. In the Phase III BL-B01D1-307 trial, iza ...
I'm A Colorectal Cancer Doctor. Here Are 5 Things I'd Never Do.
Here's How To Know If You Should Get Tested. 2. I'd never miss or delay colonoscopies and screening tests. Cases of colorectal cancer have been rapidly increasing among young adults. Though the disease, which affects fewer than 1% of adults, is still rare, the spike in incidence has made early screening and diagnosis all the more important.
